# Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer

> **NCT00484432** · PHASE2 · COMPLETED · sponsor: **AGC Biologics S.p.A.** · enrollment: 37 (actual)

## Conditions studied

- Ovarian Cancer Metastatic Recurrent

## Interventions

- **DRUG:** NGR-hTNF
- **DRUG:** doxorubicin

## Key facts

- **NCT ID:** NCT00484432
- **Lead sponsor:** AGC Biologics S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2018-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00484432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00484432, "Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00484432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*